| TA194 |
Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal) (TA194) |
|
-
-
prostate cancer
Fast, easy summary view of NICE guidance on 'prostate cancer'
-
-
-
Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer
NICE is unable to recommend the use in the NHS of denosumab for the treatment of therapy-induced bone loss in people with non-metastatic prostate cancer because no evidence submission was received from the manufacturer or sponsor of the technology.
-
Other information
NICE Pathways
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: prostate cancer
How this guidance was produced
Background information
- None found
This page was last updated: 26 October 2011
-
-
Guidance formats
-
Implementation tools and resources
- None available
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
